Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.
Bustoros M, Anand S, Sklavenitis-Pistofidis R, Redd R, Boyle EM, Zhitomirsky B, Dunford AJ, Tai YT, Chavda SJ, Boehner C, Neuse CJ, Rahmat M, Dutta A, Casneuf T, Verona R, Kastritis E, Trippa L, Stewart C, Walker BA, Davies FE, Dimopoulos MA, Bergsagel PL, Yong K, Morgan GJ, Aguet F, Getz G, Ghobrial IM. Bustoros M, et al. Among authors: verona r. Nat Commun. 2022 Jun 15;13(1):3449. doi: 10.1038/s41467-022-30694-w. Nat Commun. 2022. PMID: 35705541 Free PMC article.
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, Sendecki J, Wong A, Verona RI, Sonneveld P, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ. Verkleij CPM, et al. Among authors: verona ri. Blood Adv. 2021 Apr 27;5(8):2196-2215. doi: 10.1182/bloodadvances.2020003805. Blood Adv. 2021. PMID: 33890981 Free PMC article.
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.
Girgis S, Wang Lin SX, Pillarisetti K, Verona R, Vieyra D, Casneuf T, Fink D, Miao X, Chen Y, Stephenson T, Banerjee A, Hilder BW, Russell J, Infante J, Elsayed Y, Smit J, Goldberg JD. Girgis S, et al. Among authors: verona r. Blood Adv. 2023 Feb 28;7(4):644-648. doi: 10.1182/bloodadvances.2022007625. Blood Adv. 2023. PMID: 36006441 Free PMC article. No abstract available.
Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
Holstein SA, Asimakopoulos F, Azab AK, Bianchi G, Bhutani M, Crews LA, Cupedo T, Giles H, Gooding S, Hillengass J, John L, Kaiser S, Lee L, Maclachlan K, Pasquini MC, Pichiorri F, Shah N, Shokeen M, Shy BR, Smith EL, Verona R, Usmani SZ, McCarthy PL. Holstein SA, et al. Among authors: verona r. Transplant Cell Ther. 2022 Aug;28(8):446-454. doi: 10.1016/j.jtct.2022.05.019. Epub 2022 May 21. Transplant Cell Ther. 2022. PMID: 35605882 Free PMC article.
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Usmani SZ, et al. Among authors: verona r. Lancet. 2021 Aug 21;398(10301):665-674. doi: 10.1016/S0140-6736(21)01338-6. Epub 2021 Aug 10. Lancet. 2021. PMID: 34388396 Clinical Trial.
Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Moreau P, et al. Among authors: verona r. N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35661166 Free PMC article. Clinical Trial.
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, Lau O, Calara-Nielsen K, Davis C, Patel J, Banerjee A, Stephenson T, Uhlar C, Kobos R, Goldberg J, Pei L, Trancucci D, Girgis S, Wang Lin SX, Wu LS, Moreau P, Usmani SZ, Bahlis NJ, van de Donk NWCJ, Verona RI. Cortes-Selva D, et al. Among authors: verona ri. Blood. 2024 Aug 8;144(6):615-628. doi: 10.1182/blood.2023022823. Blood. 2024. PMID: 38657201 Free PMC article. Clinical Trial.
Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.
DeAngelis N, Ferrante C, Powers G, Sendecki J, Mattson B, Pizutti D, Packman K, Wang W, Trouba K, Nanjunda R, Wheeler J, Brittingham R, Wu SJ, Luo J, Lorenzi MV, Verona RI. DeAngelis N, et al. Among authors: verona ri. Cancer Chemother Pharmacol. 2022 Apr;89(4):515-527. doi: 10.1007/s00280-022-04415-5. Epub 2022 Mar 17. Cancer Chemother Pharmacol. 2022. PMID: 35298699 Free PMC article.
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
Palakurthi S, Kuraguchi M, Zacharek SJ, Zudaire E, Huang W, Bonal DM, Liu J, Dhaneshwar A, DePeaux K, Gowaski MR, Bailey D, Regan SN, Ivanova E, Ferrante C, English JM, Khosla A, Beck AH, Rytlewski JA, Sanders C, Laquerre S, Bittinger MA, Kirschmeier PT, Packman K, Janne PA, Moy C, Wong KK, Verona RI, Lorenzi MV. Palakurthi S, et al. Among authors: verona ri. Cancer Immunol Res. 2019 Sep;7(9):1457-1471. doi: 10.1158/2326-6066.CIR-18-0595. Epub 2019 Jul 22. Cancer Immunol Res. 2019. PMID: 31331945
61 results